Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2020 Mar 19;10:5046. doi: 10.1038/s41598-020-61251-4

Longitudinal phenotype development in a minipig model of neurofibromatosis type 1

Johanna Uthoff 1,2,3, Jared Larson 1, Takashi S Sato 1, Emily Hammond 1,2,3, Kimberly E Schroeder 2, Frank Rohret 4, Christopher S Rogers 4, Dawn E Quelle 3,5, Benjamin W Darbro 3,6, Rajesh Khanna 7, Jill M Weimer 9, David K Meyerholz 8, Jessica C Sieren 1,2,3,✉
PMCID: PMC7081358  PMID: 32193437

Abstract

Neurofibromatosis type 1 (NF1) is a rare, autosomal dominant disease with variable clinical presentations. Large animal models are useful to help dissect molecular mechanisms, determine relevant biomarkers, and develop effective therapeutics. Here, we studied a NF1 minipig model (NF1+/ex42del) for the first 12 months of life to evaluate phenotype development, track disease progression, and provide a comparison to human subjects. Through systematic evaluation, we have shown that compared to littermate controls, the NF1 model develops phenotypic characteristics of human NF1: [1] café-au-lait macules, [2] axillary/inguinal freckling, [3] shortened stature, [4] tibial bone curvature, and [5] neurofibroma. At 4 months, full body computed tomography imaging detected significantly smaller long bones in NF1+/ex42del minipigs compared to controls, indicative of shorter stature. We found quantitative evidence of tibial bowing in a subpopulation of NF1 minipigs. By 8 months, an NF1+/ex42del boar developed a large diffuse shoulder neurofibroma, visualized on magnetic resonance imaging, which subsequently grew in size and depth as the animal aged up to 20 months. The NF1+/ex42del minipig model progressively demonstrates signature attributes that parallel clinical manifestations seen in humans and provides a viable tool for future translational NF1 research.

Subject terms: Neurodegenerative diseases, Experimental models of disease, Translational research

Introduction

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with nearly 100% penetrance and an incidence of approximately 1 in every 3,000 births worldwide1. The clinical manifestations of the disorder are highly variable, even among individuals with the same mutation in NF11,2. The most common phenotypic presentations of NF1 include café-au-lait macules (CALMs), axillary and inguinal freckling, optic pathway gliomas, pilocytic astrocytoma, and the presence of neurofibromas and plexiform neurofibromas (PNs) that have the potential to develop into malignant peripheral nerve sheath tumors (MPNSTs)1–3. Some individuals with NF1 may exhibit learning disabilities, increased pain, short stature, or macrocephaly at birth3,4. Although uncommon, they may also be born with or develop tibial bowing and sphenoid wing dysplasia4. Those affected by NF1 are also at increased risk of developing a number of different cancers including glioblastoma, breast cancer, and leukemia1. Because of the heterogeneity, impact on quality of life, and significant morbidity associated with NF1, there is a considerable need for research into its underlying pathology and noninvasive monitoring of its progression.

Systematic study of NF1 in human subjects is a major challenge as the variability in disease presentation between individuals makes it difficult to create an effective longitudinal cohort. Medical imaging is used in the NF1 population to detect and monitor disease phenotypes including optic-pathway glioma5–7, plexiform neurofibroma and MPNST, spinal neurofibroma, tibial bowing and scoliosis. Retrospectively collected imaging studies have assessed prevalence and NF1 findings in radiograph8, computed tomography (CT)9, magnetic resonance (MR) imaging7,10,11, and positron emission tomography (PET)12. As the NF1 population is more susceptible to the effects of radiation13, prospective studies are often limited to non-ionization radiation modalities such as MR5,6,14,15 and ultrasound16,17.

Efforts to create animal models of NF1 seek to provide the opportunity to explore treatment response and natural course18–24. Several murine models of NF1 have already been developed; however, mice are too small for the relevant medical imaging systems to be used in detection and monitoring the progression of NF1’s phenotypes19–21,24. Minipigs have proven to be successful models in a range of human diseases including Huntington’s disease, ataxia-telangiectasia, cystic fibrosis, and cancer25–33. The similarities between the minipig and humans with regards to anatomy, physiology, and size allows them to be studied using the same imaging systems that are used clinically for human patients. Our previous work with minipigs has shown that a deletion of exon 42 (NF1+/ex42del), a mutation observed in NF1 patients, mimics early in life, a wide range of phenotypes exhibited by the human population including CALMs, cutaneous and/or plexiform neurofibromas, axillary and inguinal freckling, unidentified bright objects, decreased cognitive abilities22, and increased pain and sleep disturbances34. In this study, we examine and monitor the development of NF1 characteristics in a second generation of Yucatan minipig using CT and MR over the first 12-months of life. Image time points at 4, 8, and 12 months target key developmental stages corresponding to pre-puberty, adolescence and young adulthood in the pig35,36. This study provided a unique opportunity for systematic evaluation to capture the natural penetrance of phenotypical presentation and track progression of disease manifestation of NF1+/ex42del minipigs compared to sibling wildtype controls.

Results

A flowchart of the study cohort across the repeated imaging timepoints (TPs) is included as Fig. S1 with subject-level indication of phenotype development.

NF1 minipigs exhibit stable café-au-lait macules and axillary/inguinal freckling

All eight NF1+/ex42del subjects presented with multiple CALMs at the first imaging timepoint (TP1, 4 months of age), while no CALMs were present on the four wildtype subjects (Fig. 1, Fig. S2). One large marking (Fig. 1A) was encountered which spanned the dorsal-ventral length of the left side in the subject who later developed a left-sided neurofibroma. The selected lateral CALMs ranged from 10.7 mm to 47.8 mm in maximum diameter (Fig. 1A–D). No quantitative evidence of CALM growth over time was found in subjects over the three timepoints (Fig. 1E) or in the wildtype subjects (Fig. 1F). Over time, Yucatan minipig skin lightened and the shape and color of some of the CALMS changed as the animal grew in size with some markings becoming undetectable on photograph (Fig. 1C,D). Axillary/inguinal freckling was present in all NF1+/ex42del animals at 4 months of age (Fig. S2).

Figure 1.

Figure 1

Open in a new tab

Café au lait macule (CALM) findings. All NF1+/ex42del minipigs presented with mutilple CALMs (in all pannels arrows: white –visually tracked, red – longtiudinal measurment). (A) Left side of NF1+/ex42del subject at TP1 (aged 4-months) presenting with mutiple CALMs (white arrow) and one large marking (red arrow) spanning the dorsal-ventral side. (B) Right side of same subject shows more CALMs. (C) Left side of NF1+/ex42del subject at TP1 (aged 4-months) presenting with mutiple CALMs. (D) Left side of same animal at TP3 demonstrates notable skin and CALM lightening with certain markings (white) being undetectable on photograph. (E) Boxplot of longtiudinal measurment of CALM markings shows relative stability in marking size (N = 8). (F) Left side of wildtype littermate control at TP1 (4-months) presenting without evidence of CALM.

NF1 minipigs exhibit shortened stature and phenotypic trends in skeletal measurements

At the three group imaging time points, the NF1+/ex42del animals did not show significant differences in body weight compared to wildtype littermates (Mann-Whitney individual TP, p = 0.14–0.78; RM-ANOVA, p = 0.39). While NF1 minipigs trended (not significantly) to have slightly lower body weights, the mean difference in body weights between groups merged closer over time indicating minimal body mass difference between genotypes. The difference between the NF1+/ex42del mean body weight and that of the wildtype was 4 kg at TP1, 2.5 kg at TP2 and 2.1 kg at TP3 (Table S1). The uncastrated boars tended to maintain a leaner body mass than their female littermates irrespective of genotype, which can be noted on imaging (Fig. 2D,E).

Figure 2.

Figure 2

Open in a new tab

Subject with neurofibroma progression visualized with computed tomography (CT) (shown in coronal whole-body view) at (A) 4-months and (B) 12-months using the low-dose CT (LDCT) protocol and (C) 12-months using the standard-dose CT protocol. Note the granularity differences between CT and LDCT at time point 3 (TP3: 12 months of age), particularly in the areas (S1-S3) that were biopsied for histopathology. Comparison to litter-mate male wildtype with same scanning history (D) Demonstrates the ‘typical’ CT presentation of the lean body mass and hardening of uncastrated male pigs’ skin. Comparison to littermate female wildtype with same scanning history (E) shows the increased fat content in the intact female compared to intact boar. Window/level set to abdominal view.

Human NF1 subjects often present with skeletal abnormalities including macrocephaly (24–45%), short stature (20–30%), and tibial bowing (3–4%)3,37. Skeletal measurements from CT imaging demonstrate shortened stature in NF1+/ex42del minipigs at 4-months of age (Fig. 3). Bilateral symmetry was seen in the long bone measurements of both wildtype and NF1+/ex42del subjects with the largest average difference of 1 mm, or a difference of ~1 voxel, between the left and right sides. The long bones of NF1+/ex42del subjects were smaller on average (42.5–110 mm) with a higher standard deviation (2.1–6 mm) compared to their littermate wildtype controls (mean 47.4–119 mm; standard deviation 2–4 mm) (Fig. 3a). Measurement consistency assessed with Lin’s correlation coefficient (CCC) was highly repeatable for the long bones (femur, tibia, humerus, ulna, metacarpals) while metatarsals were less repeatable (CCC 0.78–0.80).

Figure 3.

Figure 3

Open in a new tab

Bone measurements taken at 4-months of age indicate skeletal differences between NF1+/ex42del (N = 8) and wildtype minipigs (N = 4). (a) long bone measurement boxplots with repeated measures’ CCC values, (b) additional long bone and cranial cavity measurement boxplots with repeated measures’ CCC values, (c) tibial bowing assessment plotted with dashed lines indicating range and median values for wildtype siblings. Definition of abbreviations: CCC – concordance correlation coefficient; L – length; W – width; NF1 – neurofibromatosis 1; mm – millimeters; *– p < 0.05; **– p < 0.01.

There was no statistical evidence of cranial differences in the NF1+/ex42del subjects based on unilateral measurements, indeed the median and quartile cranial measurements for NF1+/ex42del minipigs was smaller than their wildtype siblings (Fig. 3b). These three cranial measurements did suffer in repeatability (CCC = 0.52–0.78), indicating the need for more repeatable measures. Assessment of tibial bowing demonstrated six NF1+/ex42del minipigs with a measurement of bowing higher than the range of the controls; bilaterally (N = 2) and unilaterally (N = 4) indicating a potential phenotype (Fig. 3c). One NF1 minipig had left leg bow angle of 8.9°, which is equal to one range deviation above the largest wildtype.

NF1 minipigs develop neurofibroma which progress with longitudinal tracking

Uncastrated boars often develop a tough outer layer of skin; in Fig. 2 we demonstrate a comparison to the littermate wildtype male and littermate wildtype female at TP3 (post-puberty CT) showing the imaging difference between the neurofibroma and the skin toughening. One out of eight NF1+/ex42del minipigs developed a detectable neurofibroma. The unilateral lesion was first detected via imaging at the 8-month imaging time point (TP2) although, retrospective review of the 4-month time point (TP1) indicated potential early signs of abnormality (Figs. 2A–C and 4). In Fig. 4, we have indicated with red arrows the histopathology sampling areas on fused whole-body coronal screening stations (T2, STIR). Lateral asymmetry is demonstrated at 8-months with the appearance of the neurofibroma, while the 4-month scan indicates relative bilateral symmetry in the region. The neurofibroma was evident on CT at the 12-month time point (TP3) (Fig. 5) and appears to extend from the top of the left shoulder to the mid-abdominal flank region. By TP3 the tumor had developed both in diameter and protrusion; a final imaging time point (TP4) occurred prior to necropsy at 20 months (Fig. 5). Faint uptake of contrast can be seen in the TP4 scans with a granular appearance in MR 3D T1-weighted gradient recalled echo sequence (LAVA) sequence acquisition (Fig. 5).

Figure 4.

Figure 4

Open in a new tab

Imaging of neurofibroma subject. (A-D) Stitched stations of whole-body magnetic resonance (MR) Short Tau Inversion Recovery (STIR) and T2-weighted acquisitions for timepoint 1 (TP1: 4 months of age) (A-B: neurofibroma not detected) and timepoint 2 (TP2: 8 months of age) (C-D: neurofibroma detected). MR images are shown in mirror view with minipig’s left side on the left. Note the higher intensity region in TP2 STIR image with no comparable high intensity visualized at TP1. (E-F) Photographs taken of left-sided neurofibroma region at timepoint 4 (TP4: 20 months of age) with indicated regions of sampling (red). (G) Additional external findings in this subject included auxiliary freckling (blue) and edema on distal portion of the left foreleg (yellow) on the same side as the masses photographed in E-F.

Figure 5.

Figure 5

Open in a new tab

Final imaging timepoints (CT = TP3; MR = TP4) of neurofibroma. Timepoint 3 (TP3: 12 months of age) whole-body computed tomography (CT) scan shown in coronal view with three axial slices corresponding to three histological captures at necropsy (red, S1-S3), window/level is abdominal field. Timepoint 4 (TP4: 20 months of age) Targeted magnetic resonance (MR) acquisitions pre- and post- contrast agent for (S3 (two slices shown) and S2), window/level was kept consistent between pre-and post- contrast images.

Measurements of the neurofibroma regions were made using the World Health Organization (WHO) criteria on the LAVA post contrast scans (Fig. 6A); WHO is taken as the product of the two longest perpendicular measurements of a tumor with progressive disease defined as ≥25% increase in one lesion38. All three regions grew between imaging timepoints in both longest axial diameter and perpendicular cross length (Table S2) and at a rate >25% indicating progressive disease. The S3 region grew more in the perpendicular region (deeper) than the other two regions which had more expansive growth in longest diameter. The perpendicular growth can be attributed in part by the overall growth of the minipig in general as the longest axial diameter tended to align tangential to the thorax.

Figure 6.

Figure 6

Open in a new tab

Image feature comparison between swine neurofibroma and plexiform neurofibroma’s from human subjects. (A) World Health Organization (WHO) tumor measurement criteria for suspected neurofibroma on 3D T1-weighted gradient recalled echo sequence (LAVA), post contrast magnetic resonance (MR); indicated percentage is growth from previous timepoint. See Table S2 for criteria raw measurements of longest and perpendicular axis. (B) Quantitative imaging characteristics extracted from the regions of interest (ROIs) (S1, S2, S3) compared to those seen in the retrospective human cohort.

At necropsy, tumor tissue was excised from three regions based on clinical appearance of the tumor, and labeled S1 (least mature), S2 and S3 (most mature). The tumors sections were relatively well-defined along the deep border and excised easily. At histopathology, each of the skin tumor sample sites had evidence of neurofibroma consistent with what was previously described in the model as diffuse cutaneous neurofibroma (Fig. 7)22. Tumor samples had progressive changes that correlated with the duration of the tumor including: increased prominence of the neurovascular networks noted by increased vascular structures, progressive infiltration and effacement of the dermis/subcutis by tumor, and maturation of neurofibroma composition from myxoid to more fibrous appearance.

Figure 7.

Figure 7

Open in a new tab

Histopathology of tumor tissues collected at different stages of growth labeled as S1 (least mature), S2, and S3 (most mature). (A) Sections of S3 dermis with multifocal effacement by tumor tissue in HE (left) and MT stains sections (middle), bar = 485 µm. The neurofibroma was composed of low-moderate cellularity (HE, right) and scattered S100 positive cells (inset, right), bar = 98 µm. (B) Skin tumor sections containing epidermis and dermis in S1-3 samples, MT stained sections, bar = 966 and 194 µm (top and bottom panels, respectively). Neurofibroma tissues (black arrows) progressively expanded into and effaced much of the dermis (see S1-3). Neurofibroma tissues extended to the upper limits of the dermis but did not cross the basement membrane into the epidermis. Neurovascular networks (red arrows) were increased in prominence from S1 to S3, especially in the upper dermis. (C) Skin tumor sections from the subcutis in S1 toS3 samples, MT stain, bar = 966 and 483 µm (top and bottom panels, respectively). Top panels: From S1 to S3, neurofibromas had a more prominent fibrous appearance (i.e. increased collagen deposition evidence by increased blue staining) that also effaced normal adipocytes (white circular structures). Bottom panels: In the subcutis, cutaneous trunci muscles (see red muscle in bottom panels) had evidence of infiltration by the neurofibroma (arrows) in samples S1-2. In S3 (bottom right), the collagen-rich (blue staining) neurofibroma extended to the deep excision margins, but cutaneous trunci muscle was not detected.

NF1 Minipigs develop neurofibroma with quantitative imaging features similar to human subjects

Increasing change in signal intensity post-contrast was seen between tumor regions S1 (10.8%) and S2 (12.8%); the S3 region of interest (ROI) had the largest uptake of contrast with a percentage signal intestisty change (%SIΔ) of 13.6%. The two adjacent slices to each ROI were assessed with differences in %SIΔ between <0.1% and 0.3%. In general, an increase in signal intensity indicates permeable blood vessels characteristic of tumor tissue – specifically where the gadolinium contrast has leaked into the extracellular matrix39. Prior work has found higher rates of contrast enhancement in neurofibromas when compared to malignant peripheral nerve sheath tumors in human subjects with NF1, and further that this was negatively correlated with the degree of microscopic necrotic area11. Quantitative imaging characteristics were extracted from the three ROIs (S1, S2 and S3) and compared to previously published values for plexiform neurofibroma assessment (Fig. 6B) which showed the values for each of the three ROIs followed trends seen in a retrospective human cohort40.

Systemic imaging of minipigs allows for investigation of other findings

In our cohort of 8 NF1+/ex42del minipigs we did not see indication of optic glioma or optic chiasm tumor (Fig. S3A). Assessment of the brain did not demonstrate presence of “unidentified bright objects” which was present in the F0 boars22 and have been associated in NF1 humans with cognitive dysfunction (Fig. S3B)22,41–46. Two of the NF1+/ex42del subjects exhibited deep shoulder lesions that could not be identified upon necropsy (Fig. S3C). These lesions were consistent with a previous injury or preanesthetic delivery prior to image acquisition, as has been sometimes seen. A finding previously undescribed in MR and CT imaging was the presence of an enlarged accessory sex gland in uncastrated males (Fig. S3D) which appears bright on STIR, isointense on T2, and similar to soft-tissue on CT47. Optic gliomas are a manifestation of NF1 occurring in an estimated 15% of children with the disease. Measurement of the optic nerve and sheath indicated no significant difference (p > 0.19) between NF1+/ex42del and wildtype (Fig. S4).

Discussion

We longitudinally studied an NF1 porcine model (NF1+/ex42del) for the first 12-months of life to evaluate phenotype development, track disease progression, and provide a comparison to human subjects. Through systematic tracking we have shown that an NF1+/ex42del minipig model develops phenotypic characteristics [1] CALMs, [2] axillary/inguinal freckling, [3] shortened stature, [4] tibial bone curvature, and [5] histological variations in neurofibroma growth. With littermate wildtype controls we confirmed that these findings were exclusive to minipigs with NF1 genotype. The breadth of common NF1 phenotypes presented in this cohort indicates minipigs as a translational correlate to the diversity seen in the human presentation of NF1. Through this study we outlined a set of imaging protocols that allow for the longitudinal tracking of phenotypes and demonstrated the effectiveness of tracking on a minipig developing neurofibroma. The ability to longitudinal track neurofibroma progression with non-invasive medical imaging modalities common to human subjects is powerful for preclinical applications such as drug response assessment.

The series of imaging protocols utilized for this study were guided by recommendations from the REiNS International Collaboration which indicates that MR imaging acquisition should be optimized for tumor type/location and recommends both whole-body imaging and the STIR protocol for visualization of peripheral nerve sheath tumors48,49. However, it was noted in Dombi et al. that some clinically relevant tumors may not have good tissue definition on MR imaging with the accompanying Fig. 3a,b of that manuscript displaying a superficial flank plexiform neurofibroma48. The development of neurofibroma in a minipig model allows for robust comparison of protocols and modalities which is not possible in human subjects. We recorded the development and growth of a neurofibroma in a minipig model over the course over a 20-month period with four imaging time-points consisting of screening MR, targeted MR, and whole-body CT. We demonstrated detection of neurofibroma with LDCT and with additional testing this could suggest LDCT as a viable option for whole-body screening with reduced radiation exposure over standard CT, and as a fast acquisition (not requiring anesthesia) alternative to MR.

We performed an extensive CT-based skeletal measurement assessment in our matched cohort. Short stature is common among NF1 adults with 20–30% below the 3rd percentile in height37. We found statistically smaller long bones (femur, tibia, humerus, ulna, metacarpals) in the NF1+/ex42del minipigs compared to their wildtype siblings. Previous NF1 minipig studies found no difference in stature using external measurement of length and height23. However, prior studies have recorded strong association between femur measurement and human stature in adults50 and children51 and have been used as a surrogate measure of growth differences between rats52 and pigs53. Hence, we conclude that the significant difference in multiple bones of the NF1+/ex42del minipigs is indicative of the short stature that is associated with NF in human patients. Interestingly, the metatarsals were the only long bones to not be statistically smaller in the NF1+/ex42del minipigs; recently, Faria et al. described a potential new phenotype of NF1 in which the second toe of subjects is elevated and super-positioned on the third toe, visual assessment of minipig metatarsal arrangement did not demonstrate evidence of this characteristic54. Tibial bowing is a rare but distinctive phenotype in NF1 (3–4%)37, we report quantitative results of increased bilateral and unilateral bowing in NF1 minipigs out of the range of wildtype sibling controls, indicating a potential phenotype. Isakson et al. described bilateral tibial dysplasia narrowing in two cloned boars using qualitative radiograph assessment but did not note other skeletal abnormalities in the F1 cohort23. Weight was not statistically significantly different between NF1+/ex42del and wildtype minipigs at any of the three study time points (4, 8 and 12 months of age). Previous studies have indicated a reduced weight NF1 minipigs using a small selected cohort (N = 3)23.

The skin of the Yucatan minipig has previously been shown to have similar characteristics to human skin including epidermal thickness and melanin assessment55. This was confirmed with the presence of NF1 dermal manifestations including CALMs and axillary/inguinal freckling in all NF1+/ex42del subjects in this cohort. Over 99% of humans with NF1 present with CALMs ranging from 0.5 cm to greater than 20 cm in diameter56. Here, through longitudinal tracking of CALMs we found the minipig presentation showed similarity in size (1.0 cm–5.0 cm). One NF1+/ex42del subject in our cohort presented with a giant CALM (>20 cm in diameter) along the left side; giant CALM is a rare NF1 manifestation reported in cases of segmental sporadic NF1 mutation with associated with plexiform neurofibroma and MPNST57–59. As the minipig subjects aged, the skin tended to lighten making it difficult to visually inspect the CALMs; this is in contrast to the human population where increased skin pigmentation due to sun exposure is common56.

There are currently two NF1 minipig published models: the Yucatan NF1+/ex42del22,34 and the Ossabaw NF1p.Arg1947* 23. The two models have some similarities and variations which will benefit the research community and provide the mechanism for more individualized choices in phenotypical presentation. In our previously published Yucatan NF1+/ex42del cohort we demonstrated imaging of neurofibromas in three male NF1 pigs that also presented with CALMs22. In this study, we have tracked individual CALM from 4 to 12 months of age - correlating to prepubescence through early adulthood in humans – finding that CALMs in minipigs across this time period are stable is size. Further, we have demonstrated presence of axillary/inguinal freckling through the 12 months of age. Unlike our previous cohort of NF1+/ex42del swine, the animals presented here are the offspring of cloned boars heterozygous for the NF1 exon 42 deletion bred to wildtype sows22. There is some evidence to suggest that cloned (F0) animals may exhibit weakened immune systems and other abnormal phenotypes in adulthood, resulting in divergent health outcomes and irregular behavior60,61. In this study we have excluded those potential effects by using naturally bred first generation (F1) minipigs. Isakson et al. recently reported in an Ossabaw minipig model the development of CALMs (F0, F1), freckling (F1), Lisch nodules (F0), dermal neurofibroma (F0, F1), a glioma-like lesion in optic chiasm (F1), and tibial narrowing (F0)23. In this study’s Yucatan F1 cohort we found no evidence of optic chiasm lesion.

This study has limitations. While this is the first systematic longitudinal study of a cohort of NF1+/ex42del animals with littermate wildtype control animals, the study contained a limited number of animals (N = 12). As some clinically important NF1 phenotypes are rare in the human population, this small animal cohort may not fully represent the spectrum of phenotypes present in the NF1+/ex42del swine model. We did not systematically screen this cohort of animals for Lisch nodules or cognitive impairment. Abnormal curvatures of the spine are potential skeletal abnormality associated with NF1, however, in our study we were not able to differentiate imaging assessed spinal curvature from positional distortion in our anesthetized, prone minipigs. It is possible this could be assessed in future studies by incorporating a different positioning approach for image acquisition. This study was designed to systematically image the animal cohort for the first 12 months of age for early characterization and progression over this time-period (early childhood and adolescence). The one NF1+/ex42del animal that presented with a neurofibroma within 12 months was necropsied at 20 months. Hence, we cannot determine if further members of the cohort would have developed neurofibromas after 12 months of age - note in our prior study of the F0 cohort neurofibromas were discovered between the ages of 11 and 17 months of age22. Due to the yet unknown role of hormones on NF1 phenotype development, the male animals in this study were uncastrated which can present some challenges for longitudinal housing and scientific study. Uncastrated boars have increased aggression and sexual behaviors, along with physical characteristics such as tusk growth and thickened subcutaneous layer of tissue (aka shoulder plate). These characteristics can require individual housing and increased caution (and personnel) for transport, anesthesia administration, and recovery.

In conclusion, in-vivo, clinical equivalent medical imaging protocols including CT and MR were used to systematically evaluate early development of NF1 related phenotypes in a matched cohort of male and female NF1+/ex42del animals with littermate wildtype control animals. In this study we found penetrant presentation of shortened stature and tibial curvature. Typical skin manifestations of NF1 including CALMs and axillary/inguinal freckling were identified as stable throughout the NF1+/ex42del minipig life-course. One out of eight NF1+/ex42del animals developed a neurofibroma which progressed over time, paralleled to imaging characteristics of human neurofibromas, and demonstrated differential maturation on histopathology. This NF1+/ex42del Yucatan minipig model presents a powerful tool for optimization of medical imaging protocols and preclinical therapeutic evaluation.

Materials and Methods

Animal procedures

All procedures were approved by the Institutional Animal Care and Use Committees (IACUC) of the University of Iowa and Exemplar Genetics (Coralville, Iowa) and all procedures were performed in accordance with relevant guidelines and regulations. 12 Yucatan minipigs (6 female, 6 male), 8 heterozygous for NF1 (NF1+/ex42del) and 4 littermate wildtypes, were systematically imaged at 4-, 8-, and 12-months of age using both CT and MR imaging. Animals were anesthetized using either a combination of midazolam (0.6 mg/kg) and ketamine (2.2 mg/kg) or telazol (2.2–4.4 mg/kg), ketamine (1.1–2.2 mg/kg), and xylazine (1.1–2.2 mg/kg). Anesthesia was maintained throughout animal preparation and imaging using isoflurane (1–5%). Each pig was intubated with a balloon-cuffed endotracheal tube (6–8 mm) and mechanically ventilated using a Primer SP MRI-Compatible Veterinary Anesthesia Ventilator (DRE Veterinary). Animals were ventilated under 100% oxygen with a respiratory rate of 16-20 breaths per minute, 5cmH2O positive end expiratory pressure, and a tidal volume of approximately 10 mL/kg. Physiological monitoring was performed using electrocardiogram, oxygen saturation (SP-O2), and end tidal carbon dioxide pressure (ET-CO2). Ventilation parameters were modified when necessary to maintain a heart rate between 80–100 beats per minute and an SP-O2 of 95–100%. Prior to imaging, animals were placed in the prone position with their hind limbs extended behind them and their forelimbs fully adducted to their sides to provide stability. Mechanical ventilation was maintained throughout imaging; no breath holds were performed.

Imaging procedures

A longitudinal imaging study was devised with three proposed imaging timepoints at 4-months (TP1), 8-months (TP2), and 12-months (TP3) of age (Fig. S1). Scans were systematically reviewed at each timepoint by a radiologist (T.S.S.) specializing in pediatrics and neuroradiology using a structured method of reporting. Review was performed unblinded to known genotype (NF1+/ex42del /wildtype) and preceding timepoint scans were provided for longitudinal assessment concordant with clinical practice.

A non-contrast enhanced, full body screening CT was acquired at TP1 and TP3 using a Siemens SOMATOM Force CT scanner (Siemens Healthcare, Forcheim, Germany) or a GE Discovery MI PET/CT (GE Healthcare, Waukesha, WI). The following standard dose parameters were used for acquisition: Spiral, 70 kV, 208 ref. mAs (tube current modulation on), pitch 1.9. Data was reconstructed as 0.75 and 2 mm slice thicknesses using iterative reconstructions (Qr40, ADMIRE level 5 or STANDARD, ASiR 100%). A subsequent equivalent scan was acquired at a lower radiation dose level with the same parameters but with a 20-reference mAs.

MR imaging was performed at all timepoints using a 3.0 T General Electric Discovery MR750w. Four separate protocols were used for imaging: head, whole body, spine, and targeted. The developed protocols drew from whole-body screening recommendations and typical clinical practice48,49. The targeted protocol was used only when an unexpected or abnormal finding was identified during one of the prior three protocols. Table 1 lists the scans of each protocol and their parameters. Head scans were completed using a 32-channel head coil. Targeted scans were completed using the 8US TORSOPA abdominal coil.

Table 1.

Magnetic Resonance (MR) imaging parameters.

Protocol Scan Coil Voxel Resolution FOV TR TE Flip Angle
Head Sag FSPGR BRAVO Head 1.0 × 1.0 × 1 256 × 256 8.46 3.22 12
Sag T2 Cube Head 1.0 × 1.0 × 1 256 × 256 3000 90.52 90
FLAIR Head 0.47 × 0.47 × 1 512 × 512 5000 90.10 90
Whole Body Station 1 STIR Body 1.0 × 1.0 × 1 512 × 512 9500 45.08 111
Station 1 T2 Body 1.0 × 1.0 × 1 512 × 512 3800 104.61 111
Station 2 STIR Body 0.82 × 0.82 × 5 512 × 512 9500 45.02 111
Station 2 T2 Body 0.82 × 0.82 × 5 512 × 512 4200 104.27 111
Spine Station 1 Spine Body 0.78 × 0.78 × 4 512 × 512 9500 44.46 111
Station 2 Spine Body 0.86 × 0.86 × 4 512 × 512 9500 44.35 111
Targeted Ax T2 FS PRE Abdominal 0.78 × 0.78 × 5 512 × 512 4000 104.28 111
Ax LAVA-PRE Abdominal 0.78 × 0.78 × 5 512 × 512 4.04 1.89 12
Ax LAVA -POST Abdominal 0.78 × 0.78 × 4 512 × 512 4.08 1.89 12
Open in a new tab

Sag = Sagittal plane, FSPGR = Fast Spoiled Gradient Echo, BRAVO = Brain Volume Imaging, FLAIR = Fluid Attenuated Inversion Recovery, STIR = Short Tau Inversion Recovery, LAVA = Liver Acquisition with Volume Acceleration, Ax = Axial plane, PRE = pre-contrast administration, POST = post-contrast administration, FOV = Field of View, TR = Repetition Time, TE = Time to Echo.

Clinical measurements and recording

At each imaging timepoint, minipig weight and exterior clinical indications were recorded. With the anesthetized minipig positioned laterally, photographs were taken the right and left sides. Additional photographs of encountered phenotypes were taken including CALMs, axillary and inguinal freckling, and exterior indications of neurofibroma. For each minipig exhibiting CALMs, the diameter of the largest marking on each side was measured and tracked for change across the imaging timepoints. A description of this method is included as Supplemental Text.

Skeletal measurements

Using the CT scans from TP1, skeletal measurements were taken with tools available in 3D Slicer (https://www.slicer.org/) to identify any developmental abnormalities typically seen in NF1 patients. A full description with images of these CT based skeletal measurements is included as Supplemental Text. To summarize, length measurements were made of the long bones on both lateral sides including the femur, tibia, humerus, ulna, metacarpals, and metatarsals. Presence of anterolateral tibia bowing was assessed using an angle measurement previously described in an NF1 mouse model62.

Optic nerve measurements

Longitudinal measurements of the optic nerves from head MR images were obtained using a method previously described63. A full description with images of measurements is included as Supplemental Text. To summarize, measurements of the diameter of the optic nerve with and without the nerve sheath were taken from the axial plane of the T2 CUBE datasets. These diameters were systematically measured at 3 mm behind the ocular globe in the image slice that provided the clearest view of the nerve.

Histopathology neurofibroma assessment

For minipig tumor development assessment, at necropsy tissue was taken from identified sites of interest (Fig. 2). At each site, tumor tissue was excised and samples collected from epidermal/dermal region as well as the subcutis and deep tumor margins. Tumor tissues were fixed (10% neutral buffered formalin x 5–7 days), processed, paraffin-embedded, sectioned (~4 µm) and stained for hematoxylin and eosin (HE) or Masson’s Trichrome (MT) stains. S100 immunohistochemistry was performed as detailed previously64. Tissues were examined by a veterinary pathologist following principles of reproducible histopathological examination and scoring65. As the tissues came from the same animal and were used principally for comparative descriptions, masking of the samples was not necessary.

Imaging-based neurofibroma assessment

The corresponding regions for histopathology were assessed in the T2 FS, LAVA Pre- and LAVA Post- contrast scans for quantitative imaging characteristics. Measurements of the neurofibroma regions were made using the World Health Organization (WHO) criteria on the LAVA post contrast MR scans; WHO is taken as the product of the two longest perpendicular measurements of a tumor, progressive disease is defined as ≥25% increase in one lesion38. Regions of interest (ROI) corresponding to biopsy zones were extracted from axial slices as regions with consistent area of 1400 square pixels. Percentage signal intensity change (%SIΔ) was extracted from the ROIs as previously described66. Additional quantitative imaging features (T2 Mean, T2 Entropy, T2 Skewness, and LAVA-Pre Kurtosis) were extracted and compared to published values on retrospective human clinical subjects with benign plexiform neurofibromas40.

Statistical analysis

A two-sample Wilcoxon rank sum (Mann-Whitney) test was performed between NF1+/ex42del and wildtype minipig weight and skeletal measurements67. For the ten subjects with three timepoints, subject weight growth across time was compared using repeated measures analysis of variance (RM-ANOVA) following assessment of Mauchly’s sphericity test with two degrees of freedom68. An alpha value of 0.05 was used to establish significance on a statistical level. Repeated skeletal measurements were compared using Lin’s concordance correlation coefficient (CCC) with a value ≥0.90 considered repeatable69.

Supplementary information

Supplementary information. (106.9MB, docx)

Acknowledgements

The authors would like to acknowledge the following individuals for technical assistance: Judy Rohret, Jason Struzynski, Kelly Stark, Melissa Saylor, Jarron Atha, Dan Thedens, Marla Kleingartner, Autumn Craig, Kori Rich, Adam Goeken, Mariah Leidinger, Susan Walsh, Michael Acevedo, Tony Smith, and Kevin Knoernschild. This work was supported by funding from the Synodos for NF1 program at the Children’s Tumor Foundation to DKM, BWD, CSR, JCS, DEQ, and JMW and an NCI Core grant (P30CA086862) to the University of Iowa Holden Comprehensive Cancer Center. NIH shared instrumentation awards were used to purchase both the CT (S10OD018526) and the MR (S10OD02502501) scanners utilized in this study.

Author contributions

J.U., D.K.M. and J.C.S. wrote the main manuscript text, with editing provided by C.S.R., D.Q., B.W.D., R.K. and J.M.W., J.U., J.L., E.H., F.R., J.C.S. and C.S.R. contributed to data collection. J.U., J.L., T.S.S., K.E.S., D.K.M. and J.C.S. performed data analysis and figure creation. All authors reviewed the manuscript.

Data availability

The datasets generated during and/or analyzed during the current study are partially available in the Synapse (Sage Bionetworks) Children’s Tumor Foundation repository; https://www.synapse.org/#!Synapse:syn6135075/wiki/470486. The datasets generated during and/or analyzed during the current study that are not available via Synapse, are available from the corresponding author on reasonable request.

Competing interests

CSR and FR are employees of Exemplar Genetics, a company with commercial interests in the NF1 porcine model.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

is available for this paper at 10.1038/s41598-020-61251-4.

References

  • 1.Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. The Lancet Neurology. 2014;13:834–843. doi: 10.1016/S1474-4422(14)70063-8. [DOI] [PubMed] [Google Scholar]
  • 2.Yap YS, et al. The NF1 gene revisited – from bench to bedside. Oncotarget. 2014;5:5873–5892. doi: 10.18632/oncotarget.2194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype–phenotype relationships. Human Genetics. 2017;136:349–376. doi: 10.1007/s00439-017-1766-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Florent E, et al. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. American Journal of Medical Genetics Part A. 2009;149A:2327–2338. doi: 10.1002/ajmg.a.33045. [DOI] [PubMed] [Google Scholar]
  • 5.Blanchard G, et al. Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology. Society. 2016;20:275–281. doi: 10.1016/j.ejpn.2015.12.002. [DOI] [PubMed] [Google Scholar]
  • 6.Sellmer L, et al. Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1. Orphanet journal of rare diseases. 2018;13:62. doi: 10.1186/s13023-018-0811-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Trevisson E, et al. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1. Journal of neuro-oncology. 2017;134:279–287. doi: 10.1007/s11060-017-2517-6. [DOI] [PubMed] [Google Scholar]
  • 8.Jain VV, Berry CA, Crawford AH, Emans JB, Sponseller PD. Growing Rods Are an Effective Fusionless Method of Controlling Early-Onset Scoliosis Associated With Neurofibromatosis Type 1 (NF1): A Multicenter Retrospective Case Series. Journal of pediatric orthopedics. 2017;37:e612–e618. doi: 10.1097/bpo.0000000000000963. [DOI] [PubMed] [Google Scholar]
  • 9.Ueda K, et al. Computed tomography (CT) findings in 88 neurofibromatosis 1 (NF1) patients: Prevalence rates and correlations of thoracic findings. European journal of radiology. 2015;84:1191–1195. doi: 10.1016/j.ejrad.2015.02.024. [DOI] [PubMed] [Google Scholar]
  • 10.Salman MS, Hossain S, Alqublan L, Bunge M, Rozovsky K. Cerebellar radiological abnormalities in children with neurofibromatosis type 1: part 1 - clinical and neuroimaging findings. Cerebellum & ataxias. 2018;5:14. doi: 10.1186/s40673-018-0093-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Matsumine A, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. Journal of Cancer Research and Clinical Oncology. 2009;135:891–900. doi: 10.1007/s00432-008-0523-y. [DOI] [PubMed] [Google Scholar]
  • 12.Bredella MA, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR. American journal of roentgenology. 2007;189:928–935. doi: 10.2214/ajr.07.2060. [DOI] [PubMed] [Google Scholar]
  • 13.Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations. Pediatric Radiology. 2009;39:27–31. doi: 10.1007/s00247-008-1015-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Nguyen R, Dombi E, Akshintala S, Baldwin A, Widemann BC. Characterization of spinal findings in children and adults with neurofibromatosis type 1 enrolled in a natural history study using magnetic resonance imaging. Journal of neuro-oncology. 2015;121:209–215. doi: 10.1007/s11060-014-1629-5. [DOI] [PubMed] [Google Scholar]
  • 15.Payne JM, et al. Longitudinal assessment of cognition and T2-hyperintensities in NF1: an 18-year study. American journal of medical genetics. Part A. 2014;164a:661–665. doi: 10.1002/ajmg.a.36338. [DOI] [PubMed] [Google Scholar]
  • 16.Winter N, et al. Ultrasound assessment of peripheral nerve pathology in neurofibromatosis type 1 and 2. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2017;128:702–706. doi: 10.1016/j.clinph.2017.02.005. [DOI] [PubMed] [Google Scholar]
  • 17.Stevenson DA, et al. Quantitative Ultrasound and Tibial Dysplasia in Neurofibromatosis Type 1. Journal of clinical densitometry: the official journal of the International Society for Clinical Densitometry. 2018;21:179–184. doi: 10.1016/j.jocd.2017.03.004. [DOI] [PubMed] [Google Scholar]
  • 18.Shin J, et al. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Disease models & mechanisms. 2012;5:881–894. doi: 10.1242/dmm.009779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jacks T, et al. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nature genetics. 1994;7:353–361. doi: 10.1038/ng0794-353. [DOI] [PubMed] [Google Scholar]
  • 20.Brannan CI, et al. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes & development. 1994;8:1019–1029. doi: 10.1101/gad.8.9.1019. [DOI] [PubMed] [Google Scholar]
  • 21.Zhu Y, et al. Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. Genes & development. 2001;15:859–876. doi: 10.1101/gad.862101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.White, K. A. et al. A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI insight3, 10.1172/jci.insight.120402 (2018). [DOI] [PMC free article] [PubMed]
  • 23.Isakson SH, et al. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology. 2018;1:158. doi: 10.1038/s42003-018-0163-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Li K, et al. Mice with missense and nonsense NF1 mutations display divergent phenotypes compared with human neurofibromatosis type I. Disease models & mechanisms. 2016;9:759–767. doi: 10.1242/dmm.025783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Prather RS, Lorson M, Ross JW, Whyte JJ, Walters E. Genetically Engineered Pig Models for Human. Diseases. Annual review of animal biosciences. 2013;1:203–219. doi: 10.1146/annurev-animal-031412-103715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rogers CS, et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science (New York, N.Y.) 2008;321:1837–1841. doi: 10.1126/science.1163600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Schachtschneider KM, et al. A validated, transitional and translational porcine model of hepatocellular carcinoma. Oncotarget. 2017;8:63620–63634. doi: 10.18632/oncotarget.18872. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sieren JC, et al. Development and translational imaging of a TP53 porcine tumorigenesis model. The Journal of clinical investigation. 2014;124:4052–4066. doi: 10.1172/jci75447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Askeland, G. et al. A transgenic minipig model of Huntington’s disease shows early signs of behavioral and molecular pathologies. Disease models & mechanisms11, 10.1242/dmm.035949 (2018). [DOI] [PMC free article] [PubMed]
  • 30.Beraldi R, et al. A novel porcine model of ataxia telangiectasia reproduces neurological features and motor deficits of human disease. Human molecular genetics. 2015;24:6473–6484. doi: 10.1093/hmg/ddv356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Katalan S, et al. A novel swine model of ricin-induced acute respiratory distress syndrome. Disease models & mechanisms. 2017;10:173–183. doi: 10.1242/dmm.027847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Renner, S. et al. Mild maternal hyperglycemia in INSC93S transgenic pigs causes impaired glucose tolerance and metabolic alterations in neonatal offspring. Disease Models & Mechanisms12, dmm039156, 10.1242/dmm.039156 (2019). [DOI] [PMC free article] [PubMed]
  • 33.Perleberg, C., Kind, A. & Schnieke, A. Genetically engineered pigs as models for human disease. Disease models & mechanisms11, 10.1242/dmm.030783 (2018). [DOI] [PMC free article] [PubMed]
  • 34.Khanna, R. et al. Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1. Pain, 10.1097/j.pain.0000000000001648 (2019). [DOI] [PMC free article] [PubMed]
  • 35.Howroyd PC, Peter B, de Rijk E. Review of Sexual Maturity in the Minipig. Toxicologic pathology. 2016;44:607–611. doi: 10.1177/0192623316642881. [DOI] [PubMed] [Google Scholar]
  • 36.Myrie SB, MacKay DS, Van Vliet BN, Bertolo RF. Early programming of adult blood pressure in the low birth weight Yucatan miniature pig is exacerbated by a post-weaning high-salt-fat-sugar diet. British Journal of Nutrition. 2012;108:1218–1225. doi: 10.1017/S0007114511006696. [DOI] [PubMed] [Google Scholar]
  • 37.Karwacki, M. W. & Wozniak, W. (2012).
  • 38.Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute. 2000;92:205–216. doi: 10.1093/jnci/92.3.205. [DOI] [PubMed] [Google Scholar]
  • 39.O’Connor JP, et al. Dynamic contrast-enhanced imaging techniques: CT and MRI. The British journal of radiology. 2011;84 Spec No 2:S112–120. doi: 10.1259/bjr/55166688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Uthoff J, et al. Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors. Journal of neuroradiology. Journal de neuroradiologie. 2019;46:179–185. doi: 10.1016/j.neurad.2018.05.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bassi B, Vannelli S, Giraudo MC, Burdino E, Rigardetto R. [Unidentified bright objects and neuropsychiatric disturbances] Minerva pediatrica. 2013;65:371–381. [PubMed] [Google Scholar]
  • 42.Goh WH, Khong PL, Leung CS, Wong VC. T2-weighted hyperintensities (unidentified bright objects) in children with neurofibromatosis 1: their impact on cognitive function. Journal of child neurology. 2004;19:853–858. doi: 10.1177/08830738040190110201. [DOI] [PubMed] [Google Scholar]
  • 43.Hyman SL, Gill DS, Shores EA, Steinberg A, North KN. T2 hyperintensities in children with neurofibromatosis type 1 and their relationship to cognitive functioning. Journal of neurology, neurosurgery, and psychiatry. 2007;78:1088–1091. doi: 10.1136/jnnp.2006.108134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Piscitelli O, Digilio MC, Capolino R, Longo D, Di Ciommo V. Neurofibromatosis type 1 and cerebellar T2-hyperintensities: the relationship to cognitive functioning. Developmental medicine and child neurology. 2012;54:49–51. doi: 10.1111/j.1469-8749.2011.04139.x. [DOI] [PubMed] [Google Scholar]
  • 45.Moore BD, Slopis JM, Schomer D, Jackson EF, Levy BM. Neuropsychological significance of areas of high signal intensity on brain MRIs of children with neurofibromatosis. Neurology. 1996;46:1660–1668. doi: 10.1212/wnl.46.6.1660. [DOI] [PubMed] [Google Scholar]
  • 46.Chabernaud C, et al. Thalamo-Striatal T2-Weighted Hyperintensities (Unidentified Bright Objects) Correlate With Cognitive Impairments in Neurofibromatosis Type 1 During Childhood. Developmental Neuropsychology. 2009;34:736–748. doi: 10.1080/87565640903265137. [DOI] [PubMed] [Google Scholar]
  • 47.Clark SG, Althouse GC. B-mode ultrasonographic examination of the accessory sex glands of boars. Theriogenology. 2002;57:2003–2013. doi: 10.1016/S0093-691X(02)00698-2. [DOI] [PubMed] [Google Scholar]
  • 48.Dombi E, et al. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013;81:S33–40. doi: 10.1212/01.wnl.0000435744.57038.af. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Ahlawat S, et al. Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016;87:S31–39. doi: 10.1212/wnl.0000000000002929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hauser R, Smolinski J, Gos T. The estimation of stature on the basis of measurements of the femur. Forensic science international. 2005;147:185–190. doi: 10.1016/j.forsciint.2004.09.070. [DOI] [PubMed] [Google Scholar]
  • 51.Feldesman MR. Femur/stature ratio and estimates of stature in children. American journal of physical anthropology. 1992;87:447–459. doi: 10.1002/ajpa.1330870406. [DOI] [PubMed] [Google Scholar]
  • 52.Stalvey MS, et al. Reduced bone length, growth plate thickness, bone content, and IGF-I as a model for poor growth in the CFTR-deficient rat. PloS one. 2017;12:e0188497. doi: 10.1371/journal.pone.0188497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Rogan MP, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:20571–20575. doi: 10.1073/pnas.1015281107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Faria LPG, Rodrigues LdO, Diniz LM, Rezende NA. d. & Rodrigues, L. O. C. Prevalência de um fenotipo inédito na Neurofibromatose do Tipo 1-Dados preliminares. Revista Médica de Minas Gerais. 2012;22:363–368. [Google Scholar]
  • 55.Eggleston TA, et al. Comparison of two porcine (Sus scrofa domestica) skin models for in vivo near-infrared laser exposure. Comparative medicine. 2000;50:391–397. [PubMed] [Google Scholar]
  • 56.Shah KN. The diagnostic and clinical significance of cafe-au-lait macules. Pediatric clinics of North America. 2010;57:1131–1153. doi: 10.1016/j.pcl.2010.07.002. [DOI] [PubMed] [Google Scholar]
  • 57.Yang CC, Happle R, Chao SC, Yu-Yun Lee J, Chen W. Giant cafe-au-lait macule in neurofibromatosis 1: a type 2 segmental manifestation of neurofibromatosis 1? Journal of the American Academy of Dermatology. 2008;58:493–497. doi: 10.1016/j.jaad.2007.03.013. [DOI] [PubMed] [Google Scholar]
  • 58.Tong HX, Li M, Zhang Y, Zhu J, Lu WQ. A novel NF1 mutation in a Chinese patient with giant cafe-au-lait macule in neurofibromatosis type 1 associated with a malignant peripheral nerve sheath tumor and bone abnormality. Genetics and molecular research: GMR. 2012;11:2972–2978. doi: 10.4238/2012.July.10.6. [DOI] [PubMed] [Google Scholar]
  • 59.Choudhary SV, Dhope AA, Singh R, Tidke P. Plexiform Neurofibroma Overlying Giant Cafe-au-lait Macule. Indian dermatology online journal. 2017;8:159–160. doi: 10.4103/2229-5178.202270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Wells D. Animal cloning: problems and prospects. Revue Scientifique Et Technique-Office International Des Epizooties. 2005;24:251. doi: 10.20506/rst.24.1.1566. [DOI] [PubMed] [Google Scholar]
  • 61.Carroll, J., Carter, B., Korte, S., Dowd, S. & Prather, R. The acute-phase response of cloned pigs following an immune challenge. Vol. 83 (2005). [DOI] [PubMed]
  • 62.Wang W, et al. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Human molecular genetics. 2011;20:3910–3924. doi: 10.1093/hmg/ddr310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Geeraerts T, et al. Use of T2-weighted magnetic resonance imaging of the optic nerve sheath to detect raised intracranial pressure. Critical care (London, England) 2008;12:R114. doi: 10.1186/cc7006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Meyerholz DK, et al. Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2017;65:607–618. doi: 10.1369/0022155417729357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Meyerholz DK, Beck AP. Principles and approaches for reproducible scoring of tissue stains in research. Laboratory investigation; a journal of technical methods and pathology. 2018;98:844–855. doi: 10.1038/s41374-018-0057-0. [DOI] [PubMed] [Google Scholar]
  • 66.Tu W, et al. Evaluation of a free-breathing respiratory-triggered (Navigator) 3-D T1-weighted (T1W) gradient recalled echo sequence (LAVA) for detection of enhancement in cystic and solid renal masses. European radiology. 2019;29:2507–2517. doi: 10.1007/s00330-018-5839-7. [DOI] [PubMed] [Google Scholar]
  • 67.Mann, H. B. & Whitney, D. R. On a test of whether one of two random variables is stochastically larger than the other. The annals of mathematical statistics, 50-60 (1947).
  • 68.Hopkins KD, Glass GV. Research design and analysis clinic: The analysis of repeated measures and other mixed-model ANOVA designs. The Journal of Special Education. 1972;6:185–188. doi: 10.1177/002246697200600211. [DOI] [Google Scholar]
  • 69.Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics. 1989;45:255–268. doi: 10.2307/2532051. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary information. (106.9MB, docx)

Data Availability Statement

The datasets generated during and/or analyzed during the current study are partially available in the Synapse (Sage Bionetworks) Children’s Tumor Foundation repository; https://www.synapse.org/#!Synapse:syn6135075/wiki/470486. The datasets generated during and/or analyzed during the current study that are not available via Synapse, are available from the corresponding author on reasonable request.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES